

PHARMANUTRA S.P.A.: LAUNCH OF THE MTA STAR SEGMENT LISTING APPROVED BY THE BOARD OF DIRECTORS

Pisa, 21st September 2020 - [PharmaNutra S.p.A.](#) (the "Company"), Tuscan nutraceutical company, leader in the iron nutritional supplements sector, listed on the AIM Italia (Ticker: PHN) market, hereby communicates that its Board of Directors today approved the launch of the Company's share listing process on the Mercato Telematico Azionario organized by Borsa Italiana S.p.A. (Italian Stock Exchange) ("MTA"), STAR segment (the "Listing").

In order to implement the project, however subordinate to obtaining competent Authority authorisations, the ordinary and extraordinary Shareholders' Meetings will be called in October 2020 to make the necessary resolutions.

The Company also communicates that, subordinate to the shares being admitted to trading on the MTA and effective from the date their trading starts, it intends to adhere to the simplification system established by arts. 70, paragraph 8, and 71, paragraph 1-bis of the Issuers' Regulation. So will hence avail itself of the right to be exempted of obligations to publish the information documents established by arts. 70, paragraph 6, and 71, paragraph 1, of said Issuers' Regulation for significant merger, splitting, increase in capital transactions through contribution of assets in kind, acquisitions and transfers.

PharmaNutra S.p.A.

Founded and led by the President Andrea Lacorte and Vice President Roberto Lacorte, PharmaNutra was established in 2003. It develops unique nutritional supplements and innovative nutritional devices, handling the entire production process, from proprietary raw materials to finished product. The efficacy of the products has been demonstrated with a wealth of scientific evidence, with 112 studies published involving more than 7000 subjects. The Group distributes and sells its products in Italy and abroad. In Italy, products are sold through a network of 140 Pharmaceutical Representatives serving doctors and also exclusively selling PharmaNutra products to pharmacies throughout Italy. Products are sold in over 50 countries abroad, through 34 partners selected from among the finest pharmaceutical companies. PharmaNutra leads the market in the production of iron-based nutritional supplements under the SiderAL® brand, where it boasts a number of important patents on Sucrosomial® technology. Over the years, the Group has developed a precise strategy for the management and production of intellectual property, founded on the integrated management of all the various elements: proprietary raw materials, patents, brands and clinical evidence.

PharmaNutra.it

For information:

PharmaNutra S.p.A.

Via Delle Lenze, 216/b
56122 Pisa
Tel. +39 050 7846500
investorrelation@pharmanutra.it
Internal Press Office
press@calabughi.com

**Nomad
CFO SIM S.p.A.**

Via dell'Annunciata, 23/4
20121 Milan
Tel. +39 02 303431
ecm@cfsim.com

**Press Office
Spriano Communication & Partners**

Via Santa Radegonda, 16
20121 Milan
Tel. +39 02 83635708

Matteo Russo
mrusso@sprianocommunication.com
Cristina Tronconi
ctronconi@sprianocommunication.com